Ankur Drugs & Pharma Ltd
Overall Rating:  [0/5]Total Votes [ ] |
|
Initiated in the year 1995, Ankur Drugs & Pharma Ltd was previously known as Mridol Pharmaceuticals Limited. Listed with the Registrar of Companies, Maharashtra headquartered at Mumbai, the firm was authorized to begin its business operations on 7 March 1995.
At its incorporation, the firm was endorsed by two eminent people Shri Harinarayan Attal and Shri Sandeep Parwal, who later in 1996, introduced Public Subscription of 57, 00,000 Equity stocks traded at Rs 10 per share. It was in 1998, the name of the firm was altered to Mridol Pharmaceuticals Limited.
At present Ankur Drugs & Pharma Ltd produces around 400 drugs for various quantity forms which range from Dry syrups to tablets, Capsules to Liquid Orals, etc. Since, its initiation Ankur has concentrated on its major trade of indenture production.
Company Expansion
Since the last six years the company has not diluted its equity base. Ankur's debt level appears high primarily because of “Expansion for Growth”. Ankur has used its debts mostly to fund the core business expansion at Baddi by creating production facility for “best in world”.
Currently company operates in the ratio of 40% Loan License and 60% Third Party which it proposes to be 50:50 in coming future. Looking at the current business model company’s basic strategy is to approach big domestic players for contract manufacturing in formulations and maintain a sustainable net margin of 10% in their overall business. The company is targeting to grow multifold in coming years through contract manufacturing.
The company has recently announced that it will invest in the entire paid up share capital of TVC Life Sciences Ltd. in order to make it its wholly owned subsidiary. The group is engaged in manufacturing of pharma formulation in various dosage forms for leading Indian Companies. It is into 100% Contract Manufacturing activity and the plants are strategically located offering varied financial advantages to its customers.
Brand Umbrella of Ankur Drugs & Pharma Ltd
ADPL is presently producing its products under some of the following brands:
Below is the list of some of the prominent firms that features in the list of Ankur Drugs & Pharma Ltd clientele:
The firm is seeking for several global authorizations for the expansion of its Baddi Plant from EU MHRA and US FDA. The development of the Baddi Project would assist the firm in commencing and growing its export business.
The approximate net earnings of Ankur Drugs & Pharma Ltd are USD 191.349 Millions along with the total market capital of ` 4033 Millions. The total earning of the firm in the fiscal year 2009 was registered at ` 9682.6 Millions. In the same financial year the net profit of Ankur Drugs & Pharma Ltd was recorded at ` 371.3 Millions.
Contact Details
20th Floor, Lotus Business Park,
Off Andheri Link Road,
Andheri West,
Mumbai-400053,
Maharashtra
E-mail: www.ankurdrugs.com
Last updated on 7thJuly 2011
At present Ankur Drugs & Pharma Ltd produces around 400 drugs for various quantity forms which range from Dry syrups to tablets, Capsules to Liquid Orals, etc. Since, its initiation Ankur has concentrated on its major trade of indenture production.
Company Expansion
Since the last six years the company has not diluted its equity base. Ankur's debt level appears high primarily because of “Expansion for Growth”. Ankur has used its debts mostly to fund the core business expansion at Baddi by creating production facility for “best in world”.
Currently company operates in the ratio of 40% Loan License and 60% Third Party which it proposes to be 50:50 in coming future. Looking at the current business model company’s basic strategy is to approach big domestic players for contract manufacturing in formulations and maintain a sustainable net margin of 10% in their overall business. The company is targeting to grow multifold in coming years through contract manufacturing.
The company has recently announced that it will invest in the entire paid up share capital of TVC Life Sciences Ltd. in order to make it its wholly owned subsidiary. The group is engaged in manufacturing of pharma formulation in various dosage forms for leading Indian Companies. It is into 100% Contract Manufacturing activity and the plants are strategically located offering varied financial advantages to its customers.
Brand Umbrella of Ankur Drugs & Pharma Ltd
ADPL is presently producing its products under some of the following brands:
- Stanhist
- Romilast
- Mox
- Sporidex
- Cifran
- Secafe
- Fenak Plus
- Omesec-20
Below is the list of some of the prominent firms that features in the list of Ankur Drugs & Pharma Ltd clientele:
- Ranbaxy Laboratories Limited
- Parentral Drugs (India) Limited
- Nicholas Piramal India Limited
- Hetero Healthcare Limited
- Cipla Limited
- Torrent Pharmaceuticals Limited
- Elder Pharma Limited
- Shreya Life Sicences Pvt. Limited
- Wockhardt Limited
- Khandelwal Laboratories Pvt. Limited
- Glenmark Pharma Limited
- Blue Cross Laboratories Limited
- Sandoz (India) Pvt Limited
- Cadila Laboratories Limited
- Lyka Labs Limited
- Synthiko Formulations
- Makers Laboratories Limited
The firm is seeking for several global authorizations for the expansion of its Baddi Plant from EU MHRA and US FDA. The development of the Baddi Project would assist the firm in commencing and growing its export business.
The approximate net earnings of Ankur Drugs & Pharma Ltd are USD 191.349 Millions along with the total market capital of ` 4033 Millions. The total earning of the firm in the fiscal year 2009 was registered at ` 9682.6 Millions. In the same financial year the net profit of Ankur Drugs & Pharma Ltd was recorded at ` 371.3 Millions.
Contact Details
20th Floor, Lotus Business Park,
Off Andheri Link Road,
Andheri West,
Mumbai-400053,
Maharashtra
E-mail: www.ankurdrugs.com
Last updated on 7thJuly 2011
